Evaluation of antitumor effects following tumor necrosis factor-α gene delivery using nanobubbles and ultrasound

Cancer Science

Volumn 102, Issue 11, 2011, Pages 2082-2089

  Horie, Sachiko ^a   Watanabe, Yukiko ^a   Ono, Masao ^b   Mori, Shiro ^c   Kodama, Tetsuya ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD31 ANTIGEN; LUCIFERASE; MESSENGER RNA; NANOBUBBLE; PERFLUBUTANE; PLASMID DNA; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; BREAST CARCINOMA; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; GENE DELIVERY SYSTEM; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; SOLID TUMOR; TUMOR CELL; TUMOR VOLUME; ULTRASOUND;

ANIMALS; APOPTOSIS; CASPASE 3; DNA, RECOMBINANT; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, REPORTER; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, SCID; NANOCAPSULES; NEOPLASM PROTEINS; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53; ULTRASONICS;

EID: 80054992145     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02056.x     Document Type: Article

References (35)

1. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009; 9: 361-71.
2. Meng Y, Mauceri HJ, Khodarev NN et al. Ad.Egr-TNF and local ionizing radiation suppress metastases by interferon-beta-dependent activation of antigen-specific CD8+ T cells. Mol Ther 2010; 18: 912-20.
3. van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 2006; 11: 397-408.
4. Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin 2008; 29: 1275-88.
5. Burton ER, Libutti SK. Targeting TNF-alpha for cancer therapy. J Biol 2009; 8: 85.
6. Hao S, Su L, Guo X, Moyana T, Xiang J. A novel approach to tumor suppression using microencapsulated engineered J558/TNF-alpha cells. Exp Oncol 2005; 27: 56-60.
7. Li CY, Huang Q, Kung HF. Cytokine and immuno-gene therapy for solid tumors. Cell Mol Immunol 2005; 2: 81-91.
8. Rügg C, Dormond O, Oguey D, Lejeune FJ. Tumor necrosis factor: clinical use and mechanisms of action. Drug Resist Updat 2000; 3: 271-6.
9. Cai W, Kerner ZJ, Hong H, Sun J. Targeted cancer therapy with tumor necrosis factor-alpha. Biochem Insights 2008; 1: 5-21.
10. Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 1998; 10: 573-80.
11. Sato Y, Niitsu Y. Gene therapy of cancer using TNF gene. Tanpakushitsu Kakusan Koso 1995; 40: 2694-9.
12. Wu S, Boyer CM, Whitaker RS et al. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res 1993; 53: 1939-44.
13. Drutskaya MS, Efimov GA, Kruglov AA, Kuprash DV, Nedospasov SA. Tumor necrosis factor, lymphotoxin and cancer. IUBMB Life 2010; 62: 283-9.
14. Fisher WE. The promise of a personalized genomic approach to pancreatic cancer and why targeted therapies have missed the mark. World J Surg 2011; 35: 1766-9.
15. Ito A, Shinkai M, Honda H, Kobayashi T. Heat-inducible TNF-alpha gene therapy combined with hyperthermia using magnetic nanoparticles as a novel tumor-targeted therapy. Cancer Gene Ther 2001; 8: 649-54.
16. Kang J-H, Toita R, Katayama Y. Bio and nanotechnological strategies for tumor-targeted gene therapy. Biotechnol Adv 2010; 28: 757-63.
17. Chen R, Chiba M, Mori S, Fukumoto M, Kodama T. Periodontal gene transfer by ultrasound and nano/microbubbles. J Dent Res 2009; 88: 1008-13.
18. Horie S, Watanabe Y, Chen R, Mori S, Matsumura Y, Kodama T. Development of localized gene delivery using a dual-intensity ultrasound system in the bladder. Ultrasound Med Biol 2010; 36: 1867-75.
19. Kodama T, Aoi A, Watanabe Y et al. Evaluation of transfection efficiency in skeletal muscle using nano/microbubbles and ultrasound. Ultrasound Med Biol 2010; 36: 1196-205.
20. Watanabe Y, Horie S, Funaki Y et al. Delivery of Na/I symporter gene into skeletal muscle using nanobubbles and ultrasound: visualization of gene expression by PET. J Nucl Med 2010; 51: 951-8.
21. Guzman HR, McNamara AJ, Nguyen DX, Prausnitz MR. Bioeffects caused by changes in acoustic cavitation bubble density and cell concentration: a unified explanation based on cell-to-bubble ratio and blast radius. Ultrasound Med Biol 2003; 29: 1211-22.
22. Kodama T, Tomita N, Horie S et al. Morphological study of acoustic liposomes using transmission electron microscopy. J Electron Microsc (Tokyo) 2009; 59: 187-96.
23. Aoi A, Watanabe Y, Mori S, Takahashi M, Vassaux G, Kodama T. Herpes simplex virus thymidine kinase-mediated suicide gene therapy using nano/microbubbles and ultrasound. Ultrasound Med Biol 2008; 34: 425-34.
24. Suzuki R, Takizawa T, Negishi Y, Utoguchi N, Maruyama K. Effective gene delivery with novel liposomal bubbles and ultrasonic destruction technology. Int J Pharm 2008; 354: 49-55.
25. Watanabe Y, Aoi A, Horie S et al. Low-intensity ultrasound and microbubbles enhance the antitumor effect of cisplatin. Cancer Sci 2008; 99: 2525-31.
26. Cheung AM, Brown AS, Hastie LA et al. Three-dimensional ultrasound biomicroscopy for xenograft growth analysis. Ultrasound Med Biol 2005; 31: 865-70.
27. Kim JB, Urban K, Cochran E et al. Non-invasive detection of a small number of bioluminescent cancer cells in vivo. PLoS ONE 2010; 5: e9364.
28. Suzuki R, Namai E, Oda Y et al. Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure. J Control Release 2010; 142: 245-50.
29. Walther W, Arlt F, Fichtner I, Aumann J, Stein U, Schlag PM. Heat-inducible in vivo gene therapy of colon carcinoma by human mdr1 promoter-regulated tumor necrosis factor-alpha expression. Mol Cancer Ther 2007; 6: 236-43.
30. Araujo RP, McElwain DL. A history of the study of solid tumour growth: the contribution of mathematical modelling. Bull Math Biol 2004; 66: 1039-91.
31. Singh N, Khanna N, Sharma H, Kundu S, Azmi S. Insights into the molecular mechanism of apoptosis induced by TNF-alpha in mouse epidermal JB6-derived RT-101 cells. Biochem Biophys Res Commun 2002; 295: 24-30.
32. Olin MR, Andersen BM, Zellmer DM et al. Superior efficacy of tumor cell vaccines grown in physiologic oxygen. Clin Cancer Res 2010; 16: 4800-8.
33. Ameyar M, Shatrov V, Bouquet C et al. Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and Rb. Oncogene 1999; 18: 5464-72.
34. Donato NJ, Perez M. Tumor necrosis factor-induced apoptosis stimulates p53 accumulation and p21WAF1 proteolysis in ME-180 cells. J Biol Chem 1998; 273: 5067-72.
35. Buchanan KD, Huang SL, Kim H, McPherson DD, MacDonald RC. Encapsulation of NF-kappaB decoy oligonucleotides within echogenic liposomes and ultrasound-triggered release. J Control Release 2010; 141: 193-8.